Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) told investors Wednesday that it received positive feedback from the US Food and Drug Administration regarding its plan to develop a new intravenous version of its repurposed drug NP-120 (ifenprodil), which the company is exploring as a coronavirus (COVID-19) treatment.
Work has already begun on the synthesis of the intravenous drug by Cascade Chemistry, who have identified a potentially novel and proprietary synthetic route to the final product. Algernon said it expects the first multi-kilogram batch to be ready in early July, at which point toxicology studies can begin.
The FDA advised that a 30-day animal study would be acceptable for the toxicology program of the drug, Algernon said